ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Address
3530 JOHN HOPKINS COURT
SAN DIEGO, CA 92121
Founded
2014
Number of Employees
628
Website
http://www.immunitybio.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | $4,799 | $3,941 | $2,756 | $228 | $488 | - | - | - | - | - | $2,442 |
| Average Price | - | $19.20 | $6.99 | $4.91 | $1.65 | $1.03 | - | - | - | - | - | $6.15 |
| # Shares Purchased | - | 249,952 | 563,904 | 561,401 | 138,349 | 473,586 | - | - | - | - | - | 397,438 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | -84.4% | -57.1% | -38.9% | 81.8% | 191.3% | - | - | - | - | - | -51.2% |
| S&P 500 Return to Date | - | 173.0% | 168.6% | 129.7% | 104.9% | 93.1% | - | - | - | - | - | 133.9% |
| Excess Total Return | - | -257.3% | -225.7% | -168.6% | -23.0% | 98.2% | - | - | - | - | - | -185.0% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | 4% | 13% | 19% | 68% | 87% | - | - | - | - | - | 13% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
People also followed
Never miss an email alert when insiders at IBRX make a trade.
Creating a free account takes less than one minute